(periodontal pocket) has recently gained interest. These products provide a long-term, effective treatment at the site of infection at much smaller doses (4) . Biodegradable polymers are extensively employed in periodontal drug delivery devices because of their abundant source, lack of toxicity, and high tissue compatibility (5) . A major advantage of natural polymers is that they do not affect periodontal tissue regeneration. Amongst various natural polymers, chitosan, a deacetylated product of chitin is widely used in drug delivery devices. Since it exhibits favourable biological properties such as non-toxicity, biocompatibility (6) , biodegradability and wound healing traits (7) , it has attracted great attention in the pharmaceutical and biomedical fields.
Metronidazole (MZ), a nitroimidazole derivative, is effective against periodontal pathogens (8) (9) (10) . It is the drug of choice in the case of pathogenic Gram negative anaerobes. Systemic metronidazole has been employed in the control of chronic periodontal diseases (11, 12) . Topical metronidazole therapy has been used as an alternative (13) and as an adjunct to scaling and root planning (14) . Dental gels containing metronidazole (25%, m/V) in glyceryl monooleate have been studied (15) (16) (17) . The present study is aimed at developing chitosan biodegradable inserts of metronidazole for local long-term treatment of periodontal disease. The fabricated inserts were evaluated for their physical properties and in vitro drug release characteristics.
EXPERIMENTAL

Materials
Metronidazole was obtained as a gift sample from M/s Ranbaxy Laboratories (India). Chitosan (viscosity 0.05 Pa s), was generously donated by Cochin Fisheries Ltd (India). All other reagents used were of analytical grade.
Methods
Preparation of inserts. -Drug loaded and placebo inserts were prepared by the method described by Oungbho and Muller (18) , with modification. A homogeneous gel--like solution of chitosan was prepared by dispersing weighed amount of chitosan in 2% (V/V) acetic acid under constant stirring. Metronidazole was passed through a 53-µm sieve and dispersed in 1% (V/V) acetic acid solution. Drug dispersion was mixed with chitosan solution for 6 h. A measured amount of cross-linking agent (glutaraldehyde/ formaldehyde) was added to the solution and stirred for 6 h. Plasticizer (propylene glycol, PG) was then added to the drug-polymer mixture (Table I ). After deaerating under vacuum for 6 h, the drug-polymer mixture was poured on leveled glass moulds at 50°C and dried for 10-12 h. The films were subdivided into inserts (2 x 6 mm) by punching out. Dried films were wrapped in butter paper and stored in amber colored glass vials in a desiccator until further use.
Physical properties of inserts. -The fabricated inserts were evaluated for thickness, mass and drug content uniformity (19) . Drug content uniformity, between batches and within batches, was determined by dissolving individually weighed inserts (n = 6) in 5 mL of glacial acetic acid in a volumetric flask. After gentle swirling for an hour, the volume was made up to 100 mL with McIlvaine's buffer pH 6.6 (potassium dihydrogen orthophosphate and citric acid in water). The final pH of the buffer solution was adjusted using either 1 mol L -1 potassium dihydrogen orthophosphate solution or 0.5 mol L -1 citric acid solution, as required. The resultant solution was filtered through a G-2 glass filter (40 µm). An aliquot of the filtrate was suitably diluted and analyzed for metronidazole content at 316 nm on a UV spectrophotometer (UV-1601, Shimadzu, Japan). The thickness of the inserts was measured at 5 different randomly selected spots with a screw gauge. For mass uniformity, 10 inserts from each batch were weighed individually and their average was determined.
In vitro release studies. -Weighed inserts were placed in a stainless steel wire mesh (250 µm) holder of dimensions 4 x 8 mm and suspended in amber colored vials containing 10 mL of McIlvaine's buffer pH 6.6 (to simulate pH of gingival crevicular fluid in vitro) as the dissolution medium. The vials were stoppered and placed on a vial holder fitted in a water bath thermostated at 37 ± 1°C. At pre-determined time intervals, the dissolution medium was completely withdrawn and replaced with a fresh 10 mL portion of pre--warmed buffer, which ensured sink conditions. Since the formulations provide a high initial burst release of metronidazole, during the first 24 h drug release study, samples were collected every hour to maintain sink conditions. Metronidazole released was determined at 316 nm after suitable dilution. A dissolution study of film devoid of metronidazole was performed concurrently to nullify any interference by film materials.
Drug release kinetics. -The drug release kinetics from the fabricated inserts was evaluated using Higuchi's equation: Q = kt 1/2 (20) , where Q is the amount of drug released, k is the release constant and t is time. Further, the data was fitted to Korsmeyer-Peppas' power law equation: M t /M ¥ = Kt n (21) , where, M t /M ¥ is the fraction of drug released in time t, K is the structural and geometric constant, and n is the release exponent.
Statistical evaluation. -The in vitro data were analyzed for statistical significance using Student's t-test. The inserts were prepared by the casting method with controlled solvent evaporation. However, incorporation of plasticizer (propylene glycol) was necessary to obtain films with sufficient flexibility and allow subsequent sub-division into inserts. The plasticizer concentration was optimized to 40% (V/V). Although a lower level of propylene glycol could have been used, on drying harder inserts with little or no flexibility were obtained. The formulated inserts were evaluated for various physico-chemical properties and the results are given in Table II . The mass and thickness of the prepared inserts was in the range of 5.63 ± 0.42 to 6.04 ± 0.89 mg and 0.46 ± 0.06 to 0.49 ± 0.08 mm, respectively. The drug content was found to be in the range of 0.98 ± 0.09 to 1.07 ± 0.07 mg except for batch CM3 with 2.01 ± 0.08 mg MZ.
Drug release studies were performed by a static method. The inserts released the drug in a biphasic manner with an initial burst release followed by slow release for the next 7 days. The lowest burst release of 68% was observed with glutaraldehyde (10%, m/V) crosslinked inserts batch CM7 (1 mg MZ, PG 40%, m/m). However, further drug release was sustained for the next 7 days of the release study. The burst effect in the initial stages could be due to the release of drug entrapped on the surface of inserts. Considering the initial pathological load in the periodontal pocket, an initial burst release of anti-microbial is always desirable.
In vitro release studies show that the metronidazole to chitosan ratio plays an important role in the modulation of metronidazole release from the inserts (Fig. 1) . Drug release decreased as the chitosan ratio in the inserts increased. The release of metronidazole from batch CM3 (2 mg MZ per insert, PG 10%, m/m) was at a rate of 39 µg h -1 on day 1 in comparison with 33 µg h -1 from batch CM1 (1 mg MZ per insert, PG 10%, m/m). Thus, nearly 94 and 80% of drug was depleted, respectively, from inserts CM3 and CM1 with no cross-linking agent, in 24 h. The increased release rate from CM3 might partly due to the drug entrapped in the superficial layer of the insert. When the insert comes in contact with dissolution medium, the drug from the surface leaches into the surrounding medium, leaving a more porous polymer structure, which enables faster drug diffusion from the matrix. The release rate was found to decrease with increasing the polymer concentration. As shown in Fig. 2 , the concentration of propylene glycol in the inserts seems to affect the release rate. It was observed that as the concentration of propylene glycol increased from 10 to 40%, m/m, the rate of metronidazole release increased from 33 µg h -1 in CM1 (10%, m/m, PG) to 38 µg h -1 in CM2 (40%, m/m, PG). The change in the observed release rate was possibly due to alteration in membrane permeability caused by the modification of film hydrophilicity by the plasticizer (22) . The release rate was affected by the cross-linking of chitosan inserts (Fig. 3) . Cross--linking of the inserts with either formaldehyde or glutaraldehyde decreased the drug release rate in comparison with uncross-linked inserts (e.g., CM2, 1 mg MZ, PG 40%, m/m). However, even after cross-linking, there was no significant decrease in the burst release. Of the two aldehydes tested, glutaraldehyde as cross-linking agent was more effective in decreasing both the burst release and subsequent release rate. Chitosan-metronidazole insert, cross-linked with 10% (m/m) glutaraldehyde (CM7, 1 mg MZ per insert, PG 40%, m/m) had an initial burst release rate of 29 µg h -1 , which gradually decreased to around 1 µg h -1 at the end of 48 h. Further release rate was maintained at 1 µg h -1 to the end of day 7. The mean dissolution time (MDT) increased to 6.4 and 8.6 days, respectively, for CM6 and CM7 both containing 1 mg MZ per insert but crosslinked with 5 and 10% (m/m) glutaraldehyde, respectively. This was a significant change since the not cross-linked insert (CM2) exhibited MDT of 0.7 days. This difference in release rate is due to the decrease in the permeability coefficient of the cross-linked membrane resulting from the cross-link points (23) . A similar decrease in meloxicam release from cross-linked gelatin inserts has been reported recently (24) . Table II shows the treatment of release data according to the Higuchi equation. The results indicate that the amount of drug released per unit area (Q) increased with the square root of time. Furthermore, the release coefficient n < 0.45 for all prepared batches, suggests diffusion as the dominant release mechanism, and not a combination of swelling and erosion. The release rate constant (k) was > 0.7 for all batches. The high release rate constant was a result of the initial burst release exhibited by the inserts. 
CONCLUSIONS
The inserts exhibited burst release, which is desirable considering the initial pathogenic load in periodontal pockets, but provided sustained release for subsequent six days. The in vitro evaluation results are encouraging and need further evaluation of the inserts in patients suffering from periodontitis.
